Free Trial
OTCMKTS:ABLYF

Ablynx (ABLYF) Stock Price, News & Analysis

Ablynx logo
$50.63 0.00 (0.00%)
As of 04/30/2019

About Ablynx Stock (OTCMKTS:ABLYF)

Key Stats

Today's Range
$50.63
$50.63
50-Day Range
$50.63
$50.63
52-Week Range
$12.50
$55.04
Volume
N/A
Average Volume
5,063 shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Remove Ads
Receive ABLYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ablynx and its competitors with MarketBeat's FREE daily newsletter.

ABLYF Stock News Headlines

Musk’s real agenda in D.C.
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
See More Headlines

ABLYF Stock Analysis - Frequently Asked Questions

Ablynx's stock was trading at $50.63 at the beginning of the year. Since then, ABLYF stock has increased by 0.0% and is now trading at $50.63.
View the best growth stocks for 2025 here
.

Shares of ABLYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ABLYF
Previous Symbol
NASDAQ:ABLYF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$62.73 million
Price / Cash Flow
N/A
Book Value
$2.71 per share
Price / Book
18.68

Miscellaneous

Free Float
N/A
Market Cap
$3.81 billion
Optionable
Not Optionable
Beta
1.99

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:ABLYF) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners